Tips: Clinical Medical Device Trials: Investigator Obligations
7 Critical Obligations Every Medical Device Trial Investigator Must Fulfil Before, During, and After the Study
Medical device trial investigator obligations under IDE (Investigational Device Exemption) regulations are personal legal responsibilities that cannot be delegated. FDA can disqualify an investigator, reject study data, or refer findings to the Department of Justice if these obligations are not met. These 7 tips address the obligations that most frequently appear in FDA investigator inspection findings and Warning Letters.
21 CFR
812: The IDE Regulation That Governs Every Medical Device Trial Investigator
21 CFR Part 812 sets out the complete IDE framework, including investigator obligations at 21 CFR 812.100 and 812.110. Investigators who sign Form FDA 1572 (or the IDE agreement) take on personal responsibility for all obligations listed in the regulation. Source: 21 CFR Part 812
ISO 14155
The International Standard for Clinical Investigation of Medical Devices
ISO 14155:2020 is the international standard governing good clinical practice for medical device investigations. It defines investigator responsibilities, informed consent requirements, adverse event reporting, and documentation obligations that align with FDA IDE requirements and EU MDR clinical investigation rules. Source: ISO 14155:2020
FDA OCI
FDA Office of Criminal Investigations Can Act on Investigator Misconduct
FDA’s Office of Criminal Investigations (OCI) investigates potential criminal violations including falsification of clinical trial data, failure to obtain informed consent, and obstruction of FDA inspections. Investigator disqualification by FDA is a formal proceeding under 21 CFR 812.119. Source: FDA OCI
Quick Summary: 7 Investigator Obligations at a Glance
1
Conduct the investigation according to the signed agreement and IDE. Personal accountability begins the moment you countersign the IDE application or investigator agreement.
2
Obtain and document valid informed consent from every subject. Consent must be obtained before enrolment and documented on an IRB-approved form.
3
Report adverse device effects to the sponsor and IRB within required timeframes. Unanticipated adverse device effects (UADEs) have specific reporting timelines that must be met without exception.
4
Maintain complete and accurate case histories for every subject. Source documents must support every data point entered into the CRF and must be available for FDA inspection.
5
Permit FDA access to all records and the investigation site. Investigators must allow FDA inspectors to review any record related to the investigation and must not obstruct or limit inspection access.
6
Control the investigational device and ensure it is used only as specified. Accountability for the device includes receipt, storage, use, return, and disposal; all must be documented.
7
Ensure sub-investigators and study staff are qualified and supervised. Delegation of tasks does not transfer the investigator’s regulatory obligations. The principal investigator remains responsible for everything that happens in the study.
Medical Device Trial Investigator Obligations: 7 Tips in Full
1
Conduct the Investigation Strictly According to the IDE and Signed Agreement
WHY IT MATTERS
Under 21 CFR 812.100, the investigator must conduct the investigation in accordance with the signed investigator agreement, the investigational plan, and applicable FDA regulations. Protocol deviations that are not reported and corrected give FDA grounds to exclude affected subject data from the device’s marketing application, potentially invalidating the entire study. Source: 21 CFR 812.100
WHAT TO DO
Before enrolment begins, read the entire investigational plan and IDE application. Identify every protocol-specified procedure, visit window, and data collection requirement. Brief your study team on each. If a deviation occurs, document it immediately, assess whether IRB and sponsor notification is required, and implement a corrective action. Never alter procedures to match collected data after the fact.
COMMON MISTAKE
Treating minor deviations as self-resolving. FDA inspectors classify unreported protocol deviations as evidence of inadequate oversight regardless of whether the deviation affected a primary endpoint. Every deviation must be documented and evaluated for reportability.
PRO TIP
Maintain a deviation log from Day 1, not as a reactive document. A proactive deviation log that captures near-misses and minor variations demonstrates the oversight posture FDA expects of a qualified investigator.
2
Obtain Legally Effective Informed Consent Before Any Study Procedure
WHY IT MATTERS
21 CFR 812.110(a) requires the investigator to obtain informed consent from each subject. Under 21 CFR Part 50, consent must be obtained under conditions that provide the subject adequate time to consider participation and that minimise the possibility of coercion. Failure to obtain valid consent is one of the most frequently cited investigator deficiencies in FDA inspection reports and can result in the exclusion of every subject whose consent documentation is deficient. Source: 21 CFR Part 50
WHAT TO DO
Use only the IRB-approved, current version of the consent form. Verify the subject has read and understood the form before signing. Document the date and time of consent relative to the date and time of the first study procedure. Retain the signed original in the investigator’s trial master file and provide the subject with a copy. When amendments change risk information, obtain reconsent from all currently enrolled subjects.
COMMON MISTAKE
Using an outdated consent form after an amendment because the new IRB-approved version has not yet arrived from the IRB. Enrolment must pause until the current IRB-approved form is in hand. Using a superseded form, even briefly, creates a consent deficiency for every subject enrolled during that interval.
PRO TIP
Photograph or scan both sides of every signed consent form immediately after signing and store the digital copy in a secured, backed-up location. Physical documents can be lost or damaged; a verified digital copy provides a defensible audit trail during FDA inspections.
3
Report Unanticipated Adverse Device Effects to Sponsor and IRB Immediately
WHY IT MATTERS
21 CFR 812.150(a)(1) requires the investigator to report to the sponsor and IRB any unanticipated adverse device effect (UADE) as soon as possible but no later than 10 working days after the investigator first receives notice of the effect. UADEs that are life-threatening or that result in serious injury require immediate reporting within 5 working days. Late or missing UADE reports are a direct violation that can trigger an FDA warning letter. Source: 21 CFR 812.150
WHAT TO DO
When a potential UADE is identified, document the date and time of first awareness. Evaluate whether the event meets the UADE definition: an effect on health or safety or any life-threatening problem or death caused by, or associated with, a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or IDE application. Submit written reports to sponsor and IRB within the required window. Keep copies of all submissions in the investigator trial master file.
COMMON MISTAKE
Waiting for the sponsor’s guidance before filing a UADE report. The investigator has an independent obligation to report to the IRB regardless of whether the sponsor has made a determination. Delegating the reporting decision to the sponsor does not protect the investigator from a late-reporting finding.
PRO TIP
Set a standing internal threshold that is earlier than the regulatory deadline. If the regulatory window is 10 working days, your internal target should be 5 working days. Buffer time allows for proper documentation and review before submission rather than rushed, incomplete reports filed at the deadline.
4
Maintain Accurate and Complete Case Histories for Every Enrolled Subject
WHY IT MATTERS
Under 21 CFR 812.140(a), the investigator must prepare and maintain adequate case histories that record all observations and other data pertinent to the investigation for each individual administered the device. Inadequate source documentation is the single most common finding in FDA clinical investigator inspections. If a data point in the Case Report Form cannot be traced to a source document, FDA treats it as unverifiable and may exclude the subject or the entire dataset. Source: 21 CFR 812.140
WHAT TO DO
Ensure every CRF entry is supported by an identifiable source document: medical records, lab reports, imaging studies, device accountability logs, or contemporaneous study notes. Source documents must be dated, signed or initialled, and legible. Corrections must be made with a single line through the error, the correction written nearby, initialled, and dated. Never use correction fluid. Electronic records must comply with 21 CFR Part 11 if applicable.
COMMON MISTAKE
Entering data directly into the CRF without a corresponding source document, or treating the CRF as the source document. The CRF is a transcription tool, not an original record. Data entered into the CRF that does not appear in a pre-existing source document is considered fabricated or reconstructed.
PRO TIP
Run an internal source data verification exercise at 25% enrolment. Have someone not involved in data entry compare a random sample of CRF entries against source documents. Catching transcription errors and missing source documents early avoids a much larger reconciliation task at study close.
5
Permit Full FDA Access to All Records and the Investigation Site
WHY IT MATTERS
21 CFR 812.145 requires the investigator to permit authorised FDA employees to access and copy all records relating to the investigation and to inspect the investigation site. Obstructing an FDA inspection or limiting inspector access to records is a serious violation that can result in a clinical investigator disqualification proceeding. Investigators who are disqualified are prohibited from receiving investigational devices and their data is subject to exclusion from marketing applications. Source: 21 CFR 812.145
WHAT TO DO
If FDA presents credentials and a Notice of Inspection (FDA 482), contact your institution’s regulatory affairs office immediately and then cooperate fully. Designate a point person to accompany the inspector. Do not remove, alter, or transfer any records during an inspection. Provide working space for the inspector. Answer questions factually and within your knowledge; refer complex regulatory interpretations to your regulatory counsel.
COMMON MISTAKE
Restricting inspector access to records on the grounds that the records contain other patients’ PHI. FDA inspectors operate under their own confidentiality obligations. PHI is not a basis for limiting access to source documents that are subject to the IDE. Attempting to restrict access on these grounds creates an obstruction finding.
PRO TIP
Conduct a readiness inspection with your regulatory affairs team annually. Have them request access to records as FDA would, then evaluate how quickly and completely you can produce them. The time to discover a filing gap is during a practice exercise, not during an actual FDA inspection.
6
Control the Investigational Device and Account for Every Unit from Receipt to Disposal
WHY IT MATTERS
21 CFR 812.140(a)(2) requires the investigator to maintain records of the receipt, use, or disposition of all devices received from the sponsor. Device accountability records must show the quantity received, the quantity used per subject (with subject identifiers), the quantity returned to the sponsor, and the quantity disposed of, with the method of disposal. A device accountability discrepancy raises the possibility of commercial sale or use of the device outside the trial, which is a serious violation. Source: 21 CFR 812.140
WHAT TO DO
Maintain a device accountability log from the first device shipment. Record lot numbers, serial numbers (where applicable), receipt dates, and the subject identifier for each device used. Store devices according to the manufacturer’s specifications (temperature, humidity, sterility). At study close-out, reconcile total received against total used, returned, and disposed, and resolve any discrepancy before the close-out visit.
COMMON MISTAKE
Storing investigational devices in the same location as commercially available devices of the same type without clear segregation and labelling. Devices must be clearly labelled “For Investigational Use Only” and physically separated from commercial stock to prevent inadvertent use outside the trial.
PRO TIP
Assign one person as the device accountability coordinator. This person receives every shipment, updates the log at each use, and manages returns. Distributing accountability across multiple staff members without a single responsible person is a common source of log gaps and discrepancies.
7
Supervise Sub-Investigators and Study Staff: Delegation Does Not Transfer Accountability
WHY IT MATTERS
The principal investigator (PI) is responsible for the conduct of the entire investigation at their site, including all tasks performed by sub-investigators and study coordinators. Under 21 CFR 812.110(b), the investigator must supervise the administration or use of the device to subjects under the investigator’s supervision. Errors or misconduct by study staff are attributed to the PI when the PI has not provided adequate supervision and documented delegation of tasks to qualified personnel.
WHAT TO DO
Maintain a delegation log that lists each study team member, their qualifications, and the specific tasks they are authorised to perform. Review and update the delegation log when staff change. Verify that each delegated person has the training and experience appropriate to the task. Conduct periodic team meetings to review protocol compliance, outstanding queries, and any emerging issues. Document these meetings. The PI must be accessible to the study team and must review and sign off on key decisions.
COMMON MISTAKE
Delegating study coordination entirely to a research coordinator and then being unaware of deviations, data queries, or adverse events as they occur. The PI’s name is on the IDE agreement. Hands-off delegation that results in the PI being surprised by findings during a monitoring visit or FDA inspection is one of the clearest indicators of inadequate supervision.
PRO TIP
Schedule a standing 15-minute weekly study status meeting with all active study team members. Keep a brief written record of what was discussed. This creates a documented pattern of active oversight that is immediately available to an FDA inspector and demonstrates that the PI is engaged, not absent.
Investigator Compliance Checklist: Before, During, and After the Study
Source: 21 CFR Part 812 | FDA: Conducting Clinical Trials
Key Takeaways
Signing the agreement means accepting every obligation personally
When an investigator countersigns the IDE application or investigator agreement, they accept personal regulatory accountability for all obligations in 21 CFR Part 812. There is no contractual arrangement with the sponsor or institution that transfers this accountability away from the named investigator.
Documentation is the investigation: if it is not written down, it did not happen
FDA inspectors cannot verify verbal processes, verbal approvals, or verbal reports. Every consent obtained, every deviation identified, every adverse effect reported, and every device accounted for must appear in a contemporaneous written or electronic record. Contemporaneous means recorded at the time of the event, not reconstructed from memory later.
Delegation of tasks is not delegation of obligation: the PI is always accountable
Study coordinators, sub-investigators, and research nurses can perform many study tasks when properly trained and delegated. What they cannot do is relieve the principal investigator of regulatory accountability. Every inspection finding, every deviation, every consent deficiency, and every reporting failure is attributed to the PI unless the PI can demonstrate active, documented oversight of every delegated function. Hands-off principal investigators are the most common profile in FDA disqualification proceedings.
Frequently Asked Questions
What regulations govern investigator obligations in a medical device trial?
The primary US regulation is 21 CFR Part 812, which establishes the IDE framework and sets out specific investigator obligations at 21 CFR 812.100 (general responsibilities), 812.110 (specific responsibilities), 812.140 (records), 812.145 (inspections), and 812.150 (reports). Informed consent obligations are set out in 21 CFR Part 50. IRB requirements are at 21 CFR Part 56. Internationally, ISO 14155:2020 provides the GCP standard for medical device clinical investigations. Source: 21 CFR Part 812
What is the difference between a protocol deviation and an unanticipated adverse device effect?
A protocol deviation is any departure from the approved investigational plan, whether or not it has a direct effect on the subject. A UADE is specifically an effect on health or safety, or a life-threatening problem or death, caused by or associated with the device, that was not previously identified in the investigational plan or IDE application. A deviation can occur without producing a UADE. A UADE will almost always represent a deviation from the anticipated safety profile described in the IDE. Both require documentation; UADEs also trigger mandatory reporting timelines.
Can a principal investigator delegate the consent process to a study coordinator?
Yes, with conditions. Under 21 CFR 50.25, consent must be obtained by the investigator or by a person designated by the investigator and approved by the IRB. The delegated person must be listed on the delegation log, must be qualified by training and experience to explain the study and answer subject questions, and must be explicitly approved by the IRB. The PI retains responsibility for the adequacy of every consent obtained under their name. If the designated person fails to obtain valid consent, the PI is responsible.
How long must an investigator retain study records after the trial ends?
Under 21 CFR 812.140(d), investigators must retain records for a period of 2 years after the latter of: the date on which the investigation is terminated or completed, or the date that the records are no longer required for the purposes of supporting a premarket approval application or a notice of completion. In practice, most sponsors instruct investigators to retain records for a minimum of 15 years, particularly when the device is an implant, because long-term outcome data may be required for post-market surveillance. Follow the sponsor’s retention schedule if it exceeds the regulatory minimum.
What happens if FDA finds deficiencies during a clinical investigator inspection?
After the inspection, FDA issues an Establishment Inspection Report (EIR). If deficiencies are found, FDA may issue a Form FDA 483 (Inspectional Observations) during or after the inspection. The investigator may respond in writing. Significant deficiencies can result in a Warning Letter, which is publicly posted on FDA’s website. The most serious outcome is a Notice of Initiation of Disqualification Proceedings and Opportunity to Explain (NIDPOE) under 21 CFR 812.119, which can result in the investigator being prohibited from receiving investigational devices and having their data excluded from marketing applications.
Do these investigator obligations apply to feasibility studies and early feasibility studies?
Yes. FDA’s Early Feasibility Study (EFS) programme allows first-in-human studies of novel devices under an IDE but does not reduce investigator obligations. 21 CFR Part 812 and Part 50 apply in full to EFS studies. FDA’s guidance on EFS studies emphasises that the IDE regulations and GCP standards must be followed even when the study involves very small subject numbers or early-stage device iterations. Source: FDA: Early Feasibility Studies Guidance
What is a sponsor-investigator and does their obligation differ from a regular investigator?
A sponsor-investigator is an individual who both initiates and conducts the investigation; in other words, the same person holds both the sponsor and investigator roles under 21 CFR 812.3. A sponsor-investigator carries all investigator obligations under 21 CFR 812.100-812.150 plus all sponsor obligations under 21 CFR 812.40-812.47. This includes preparing and submitting the IDE application, monitoring the investigation, evaluating UADEs, and submitting progress and final reports to FDA. The regulatory burden on a sponsor-investigator is substantially greater than on a site investigator working under a commercial sponsor’s IDE.
Sources
Government and Regulatory Sources
- 21 CFR Part 812: Investigational Device Exemptions: the primary federal regulation governing IDE studies, including all investigator obligations at 812.100, 812.110, 812.140, 812.145, and 812.150.
- 21 CFR Part 50: Protection of Human Subjects: sets out informed consent requirements applicable to all FDA-regulated clinical investigations including IDE device studies.
- FDA: Conducting Clinical Trials: FDA guidance portal covering investigator responsibilities, inspection preparation, and adverse event reporting for clinical investigations.
- FDA Guidance: Early Feasibility Studies: Information for Sponsors and Investigators: clarifies that all IDE obligations apply to first-in-human feasibility studies.
Research and Industry Sources
- ISO 14155:2020: Clinical investigation of medical devices for human subjects: Good clinical practice: international GCP standard for medical device investigations; aligns with FDA IDE requirements and EU MDR clinical investigation rules.
- FDA Office of Criminal Investigations: FDA enforcement body with authority to investigate clinical trial fraud, data falsification, and obstruction of FDA inspections involving medical device studies.
Related VelSafe Articles
Guides
HCIR Credentialing and National Patient Safety Goals Guide
Covers the credentialing requirements for healthcare industry representatives entering clinical facilities, directly relevant to medical device sales staff who support investigational device procedures.
Law
Microlearning Safety Training Legal Requirements Explained
The four legal tests for training effectiveness that apply to IDE study team training documentation: content, comprehension, timing, and the records an FDA inspector will look for.
Insights
Mobile Elevated Work Platform Safety: 2024 Data Reveals
An evidence-first analysis of how cause-specific oversight and documentation practices prevent the most common failure modes, illustrating the investigative rigour that IDE investigators are expected to bring to adverse event identification and root cause analysis.
Clinical Medical Device: Investigator Resources
More Tips for Clinical Medical Device Professionals
VelSafe’s Tips library covers actionable compliance guidance for clinical investigators, study coordinators, device manufacturers, and medical device regulatory professionals working across FDA-regulated clinical investigation programmes.
Explore All Tips
